cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Adam Mudinillah
Contact Email
adammudinillah@staialhikmahpariangan.ac.id
Phone
+6285379388533
Journal Mail Official
adammudinillah@staialhikmahpariangan.ac.id
Editorial Address
Jorong Kubang Kaciak Dusun Kubang Kaciak, Kelurahan Balai Tangah, Kecamatan Lintau Buo Utara, Kabupaten Tanah Datar, Provinsi Sumatera Barat, Kodepos 27293.
Location
Kab. tanah datar,
Sumatera barat
INDONESIA
Journal of Biomedical and Techno Nanomaterials
Published by Yayasan Adra Karima Hubbi
ISSN : 30481120     EISSN : 30481155     DOI : 10.70177/jbtn
Core Subject : Science,
Biochemistry, Genetics & Molecular Biology
Journal of Biomedical and Techno Nanomaterials is an international forum for the publication of peer-reviewed integrative review articles, special thematic issues, reflections or comments on previous research or new research directions, interviews, replications, and intervention articles - all pertaining to the research fields of medicine, pharmaceuticals, biomaterials, biotechnology, diagnosis and prevention of diseases, biomedical devices, bioinformatics, and all other related fields of biomedical and life sciences. All publications provide breadth of coverage appropriate to a wide readership in Biomedical and Techno Nanomaterials research depth to inform specialists in that area. We feel that the rapidly growing Journal of Biomedical and Techno Nanomaterials community is looking for a journal with this profile that we can achieve together. Submitted papers must be written in English for initial review stage by editors and further review process by minimum two international reviewers.
Arjuna Subject : Biokimia, Genetika dan Biologi Molekuler - Biokimia, Genetika dan Biologi Molekuler (Lain-Lain)
Articles 5 Documents
 1 
Search results for , issue "vol. 2 no. 4 (2025)" : 5 Documents clear
HYBRID NANOZYME ENABLED BIOSENSORS FOR REAL-TIME DETECTION OF MULTI-DISEASE BIOMARKERS Loso Judijanto; Rashid Rahman; Nina Anis
Journal of Biomedical and Techno Nanomaterials Vol. 2 No. 4 (2025)
Publisher : Yayasan Adra Karima Hubbi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70177/jbtn.v2i4.2378

Abstract

The early and accurate detection of disease biomarkers is fundamental to timely diagnosis and effective treatment, yet conventional laboratory methods are often slow, costly, and require complex instrumentation. Nanozymes—nanomaterials with intrinsic enzyme-like properties—offer a promising alternative for developing robust biosensors. This study aimed to design, synthesize, and validate a novel hybrid nanozyme-enabled biosensor platform capable of the sensitive, selective, and real-time multiplexed detection of biomarkers for different diseases from a single sample. A hybrid nanozyme was synthesized by integrating platinum nanoparticles with metal-organic frameworks (MOFs) to create a material with superior catalytic activity. This hybrid nanozyme was then immobilized onto a multi-channel electrochemical sensor chip. Each channel was functionalized with specific aptamers targeting three distinct biomarkers: cardiac troponin I (a cardiac marker), prostate-specific antigen (a cancer marker), and glucose (a metabolic marker). The detection was based on the catalytic signal amplification upon biomarker binding. The platform showed excellent selectivity with negligible cross-reactivity between channels and achieved a rapid detection time of under 15 minutes. The multiplexed assay successfully and accurately quantified all three biomarkers simultaneously in complex serum samples. The hybrid nanozyme-enabled electrochemical biosensor represents a significant advancement in diagnostic technology.
ARTIFICIAL INTELLIGENCE IN MEDICINE: A DEEP LEARNING CONVOLUTIONAL NEURAL NETWORK FOR PATHOLOGICAL IMAGE ANALYSIS AND CANCER GRADING James Smith; Oliver Harris; Dito Anurogo
Journal of Biomedical and Techno Nanomaterials Vol. 2 No. 4 (2025)
Publisher : Yayasan Adra Karima Hubbi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70177/jbtn.v2i4.2480

Abstract

The histopathological analysis of tissue slides is the gold standard for cancer diagnosis and grading. However, this process is labor-intensive, time-consuming, and prone to inter-observer variability, which can affect clinical outcomes. The advent of artificial intelligence (AI), particularly deep learning, presents a transformative opportunity to enhance diagnostic precision and efficiency in pathology. This study aimed to develop, train, and validate a deep learning convolutional neural network (CNN) for the automated analysis of pathological images to accurately classify malignancies and provide reliable cancer grading. A robust CNN model was trained on a comprehensive, curated dataset of thousands of annotated digital histopathology slides from multiple cancer types. The model’s performance was rigorously evaluated against the consensus diagnoses of expert pathologists using key metrics, including accuracy, sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC-ROC). Our developed CNN model demonstrated exceptional performance, achieving an overall accuracy of 98.7% in distinguishing malignant from benign tissues. For cancer grading, the model yielded a Cohen’s Kappa score of 0.92, indicating almost perfect agreement with expert pathologists. The model also showed high robustness to variations in staining and image acquisition protocols. This research confirms that a deep learning CNN can function as a highly accurate and reliable tool for automated pathological image analysis and cancer grading. Integrating such AI systems into clinical workflows could significantly augment the capabilities of pathologists, leading to improved diagnostic consistency, reduced workload, and ultimately, better patient care.
TARGETED GENE SILENCING OF KRAS ONCOGENES IN PANCREATIC CANCER USING SIRNA-LOADED GOLD NANOPARTICLES Shakib Ahmed; Zahidul Islam; Fatimah El Balqis
Journal of Biomedical and Techno Nanomaterials Vol. 2 No. 4 (2025)
Publisher : Yayasan Adra Karima Hubbi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70177/jbtn.v2i4.2516

Abstract

Pancreatic cancer, predominantly driven by mutations in the KRAS oncogene, remains one of the most lethal malignancies due to its resistance to conventional therapies. RNA interference (RNAi) using small interfering RNA (siRNA) presents a powerful strategy to silence oncogenes, but its clinical application is liited by the poor stability and inefficient delivery of naked siRNA. This study aimed to develop and validate a targeted nanodelivery system using gold nanoparticles (AuNPs) to efficiently deliver KRAS-specific siRNA and induce potent gene silencing in pancreatic cancer cells. A nanoconjugate was synthesized by attaching thiol-modified siRNA targeting the G12D-mutant KRAS gene to PEGylated gold nanoparticles. The physicochemical properties of the siRNA-AuNPs were characterized. The platform’s efficacy was evaluated in vitro using the PANC-1 human pancreatic cancer cell line. KRAS expression was quantified via qRT-PCR and Western blot, while cellular viability and apoptosis were assessed using MTT and flow cytometry assays, respectively. The synthesized siRNA-AuNPs exhibited excellent stability and were efficiently internalized by the cancer cells. This targeted delivery resulted in a significant downregulation of KRAS mRNA and protein expression by over 75% (p < 0.01) compared to controls. Consequently, this oncogene silencing led to a substantial inhibition of cancer cell proliferation and a marked increase in apoptosis. Gold nanoparticles serve as a highly effective and robust vector for the targeted delivery of siRNA. This nanomedicine platform successfully silences the critical KRAS oncogene, inducing cell death in pancreatic cancer cells and representing a promising new avenue for targeted cancer therapy.
PHARMACEUTICAL NANOTECHNOLOGY: FORMULATION AND IN VIVO EVALUATION OF CURCUMIN-LOADED NANOSUSPENSIONS FOR ENHANCED ANTI-INFLAMMATORY EFFICACY Elisa Issusilaningtyas; Sarah Williams; Muntasir Muntasir
Journal of Biomedical and Techno Nanomaterials Vol. 2 No. 4 (2025)
Publisher : Yayasan Adra Karima Hubbi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70177/jbtn.v2i4.2523

Abstract

Curcumin, a natural polyphenol derived from Curcuma longa, is well-regarded for its potent anti-inflammatory properties. However, its therapeutic application is severely hampered by its extremely low aqueous solubility and poor oral bioavailability, which leads to suboptimal absorption and limited clinical efficacy. Pharmaceutical nanotechnology offers a promising strategy to overcome these biopharmaceutical challenges. This research aimed to formulate a stable curcumin nanosuspension to significantly enhance its dissolution rate and bioavailability, and to subsequently evaluate its improved anti-inflammatory efficacy in an in vivo model. A curcumin nanosuspension was prepared using the high-pressure homogenization technique, stabilized with Poloxamer 188. The formulation was characterized for particle size, polydispersity index (PDI), and zeta potential. An in vivo anti-inflammatory study was conducted using the carrageenan-induced paw edema model in Wistar rats, comparing the efficacy of the nanosuspension against a conventional coarse curcumin suspension. The optimized nanosuspension exhibited a narrow particle size distribution with a mean diameter of 210 nm and a zeta potential of -28.5 mV, indicating good physical stability. The in vivo evaluation demonstrated that the curcumin nanosuspension produced a significantly greater inhibition of paw edema (72.4%) compared to the coarse curcumin suspension (28.1%) at the same dose (p < 0.01). Formulating curcumin into a nanosuspension is a highly effective strategy for overcoming its inherent bioavailability limitations. This nanotechnological approach dramatically enhances curcumin’s anti-inflammatory activity, validating its potential as a powerful therapeutic agent for inflammatory conditions.
AN INJECTABLE, THERMOSENSITIVE HYDROGEL AS A CELL DELIVERY VEHICLE FOR CARDIAC REGENERATIVE MEDICINE POST-MYOCARDIAL INFARCTION T. Amirul Muttaqin; Rit Som; Anna Charalambous
Journal of Biomedical and Techno Nanomaterials Vol. 2 No. 4 (2025)
Publisher : Yayasan Adra Karima Hubbi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70177/jbtn.v2i4.2661

Abstract

Cell-based therapies for myocardial infarction (MI) are critically limited by poor acute cell retention and viability following direct injection. The harsh, ischemic microenvironment and mechanical washout result in massive cell death, neutralizing therapeutic potential and leading to failed clinical translation. This research aimed to design, synthesize, and evaluate a novel, injectable, thermosensitive hydrogel as a “pro-survival” cell delivery vehicle. The objective was to determine if this biomaterial could solve the critical failure points of retention and viability, thereby enhancing the therapeutic efficacy of mesenchymal stem cells (MSCs) post-MI. A composite hydrogel (Poloxamer/Hyaluronic Acid) was characterized in vitro for its rheological properties (LCST), mechanical stiffness, and cytoprotective capacity under ischemic stress. Its in vivo efficacy was then evaluated in a rat MI model (LAD ligation). The hydrogel+MSCs group (G5) was compared against controls (saline, MSCs-in-saline) via serial echocardiography and post-mortem histomorphometry. In vitro, the hydrogel confirmed ideal thermosensitivity (LCST 37.1°C) and cytoprotection (2.5-fold increase in ischemic cell survival). In vivo, the G5 (hydrogel+MSCs) group demonstrated significantly preserved cardiac function (LVEF 45.2%) compared to the MSCs-only group (G4: 34.1%) at 28 days. This was correlated with significantly reduced infarct size and enhanced border-zone angiogenesis. The thermosensitive hydrogel functions as an essential, enabling technology. It solves the critical failure points of acute retention and viability, demonstrating that an engineered “pro-survival” delivery vehicle is a prerequisite for the successful clinical translation of cardiac cell therapy.    

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2025 2025


Reset
Filter By Issues
All Issue Vol. 3 No. 4 (2026) Vol. 3 No. 3 (2026) Vol. 3 No. 2 (2026) Vol. 3 No. 1 (2026) Vol. 2 No. 6 (2025) Vol. 2 No. 5 (2025) Vol. 2 No. 4 (2025) Vol. 2 No. 3 (2025) Vol. 2 No. 2 (2025) Vol. 2 No. 1 (2025) Vol. 1 No. 4 (2024) Vol. 1 No. 3 (2024) Vol. 1 No. 2 (2024) Vol. 1 No. 1 (2024) More Issue